Abstract
Lung cancer remains the major cause of human mortality among all the cancer types despite the colossal amount of efforts to prevent the cancer onset and to provide the appropriate cure. Recent reports have identified that important contributors of lung cancer-related mortality are the drug resistance and aggressive tumor relapse, the characteristics contributed by the presence of lung cancer stem cells (CSCs). The identification of lung CSCs is inherently complex due to the quiescent nature of lung epithelium, which makes the distinction between the normal lung epithelium and lung CSCs difficult. Recently, multiple researches have helped in the identification of lung CSCs based on the presence or absence of certain specific types of stem cell markers. Maintenance of lung CSCs is chiefly mediated through the epigenetic modifications of their genome. In this review, we will discuss about the origin of lung CSCs and the role of epigenetic modifications in their maintenance. We will also discuss in brief the major lung CSC markers and the therapeutic approaches to selectively target this population of cells.
Keywords: Lung cancer stem cells, epigenetic reprogramming, DNA methylation, chromatin remodeling, miRNAs, stem cell markers.
Current Cancer Drug Targets
Title:Lung Cancer Stem Cells: An Epigenetic Perspective
Volume: 18 Issue: 1
Author(s): Samriddhi Shukla, Sajid Khan, Sonam Sinha and Syed Musthapa Meeran*
Affiliation:
- Laboratory of Cancer Epigenetics, Division of Endocrinology, CSIR-Central Drug Research Institute, Lucknow,India
Keywords: Lung cancer stem cells, epigenetic reprogramming, DNA methylation, chromatin remodeling, miRNAs, stem cell markers.
Abstract: Lung cancer remains the major cause of human mortality among all the cancer types despite the colossal amount of efforts to prevent the cancer onset and to provide the appropriate cure. Recent reports have identified that important contributors of lung cancer-related mortality are the drug resistance and aggressive tumor relapse, the characteristics contributed by the presence of lung cancer stem cells (CSCs). The identification of lung CSCs is inherently complex due to the quiescent nature of lung epithelium, which makes the distinction between the normal lung epithelium and lung CSCs difficult. Recently, multiple researches have helped in the identification of lung CSCs based on the presence or absence of certain specific types of stem cell markers. Maintenance of lung CSCs is chiefly mediated through the epigenetic modifications of their genome. In this review, we will discuss about the origin of lung CSCs and the role of epigenetic modifications in their maintenance. We will also discuss in brief the major lung CSC markers and the therapeutic approaches to selectively target this population of cells.
Export Options
About this article
Cite this article as:
Shukla Samriddhi, Khan Sajid, Sinha Sonam and Meeran Musthapa Syed*, Lung Cancer Stem Cells: An Epigenetic Perspective, Current Cancer Drug Targets 2018; 18 (1) . https://dx.doi.org/10.2174/1568009617666170206104623
DOI https://dx.doi.org/10.2174/1568009617666170206104623 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
mPEG-PLA Micelle for Delivery of Effective Parts of Andrographis Paniculata
Current Drug Delivery Prognostic Value of CD34 Positive Cells in the Lumen of Tumor Vessels in Breast Cancer
Current Angiogenesis (Discontinued) New Insights into the Molecular Resistance Mechanisms of Chronic Myeloid Leukemia
Current Cancer Drug Targets “Metabolic Reprogramming” in Ovarian Cancer Cells Resistant to Cisplatin
Current Cancer Drug Targets Editorial: microRNAs: Potential Targets for the Treatment of Cardiovascular Disease
Current Vascular Pharmacology Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Preclinical Evaluation of New Anthracyclines
Current Medicinal Chemistry Safety of Technosphere Inhaled Insulin
Current Drug Safety The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design Atrial Fibrillation Recurrence: The Roles of Hypertension, Duration of Atrial Fibrillation Disease, and Prolonged Signal-Averaged P Wave Duration
Current Cardiology Reviews Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Targeted Therapies in Combination with Radiotherapy in Oesophageal and Gastroesophageal Carcinoma
Current Medicinal Chemistry Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Agave (Agave spp.) and its Traditional Products as a Source of Bioactive Compounds
Current Bioactive Compounds Targeting Tumor Lymphangiogenesis: An Update
Current Medicinal Chemistry Calcium as a Molecular Target in Angiogenesis
Current Pharmaceutical Design Antisense Technologies Targeting Fatty Acid Synthetic Enzymes
Recent Patents on Anti-Cancer Drug Discovery The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Direct Evidence on the Immune-Mediated Spontaneous Regression of Human Cancer: An Incentive for Pharmaceutical Companies to Develop a Novel Anti-Cancer Vaccine
Current Pharmaceutical Design